Mad About Options: Exide Ready to Charge

The Mad About Options crew reviews Jim Cramer's recent bullish comments about Exide Technologies and offers options strategies for traders and investors. Also hear options ideas for Bristol-Meyers Squibb and Acco Brands.

09/04/08 - 09:16 AM EDT

Health Winners & Losers: Medivation

Shares of Medivation surge after announcing a major marketing deal with Pfizer.

09/03/08 - 04:45 PM EDT

Pfizer Licenses Medivation Alzheimer's Drug

Pfizer will pay $225 million up front to gain worldwide marketing rights to Dimebon.

09/03/08 - 09:57 AM EDT

Vytorin Risks Debated in Medical Journal

The cholesterol drug, produced by Schering-Plough and Merck, produced a higher rate of cancer vs. a control group in a recent study, but a larger analysis said the results are statistically insignificant.

09/02/08 - 02:29 PM EDT

Introgen Critically Hurt by FDA Advexin Snub

The regulator refused to accept an approval application for the gene therapy cancer drug, dealing a devastating blow to the company.

09/02/08 - 11:15 AM EDT

Mad About Options: Healthy Profits at JNJ

The Mad About Options crew reviews Jim Cramer's recent bullish comments about Johnson & Johnson and offers options strategies for traders and investors. Also hear options ideas for GameStop & Cal-Maine.

09/01/08 - 09:29 AM EDT

Health Winners & Losers: Pfizer

The drug maker said Friday a court in Copenhagen, Denmark, ruled in its favor on patents covering atorvastatin, the active ingredient in Lipitor.

08/29/08 - 04:34 PM EDT

Arthrocare Device Use Draws More Scrutiny

A mounting FBI probe is looking into surgeries requiring one of the company's products.

08/28/08 - 02:22 PM EDT

Health Winners & Losers: Amylin

The stock, which had dropped 40% over the last two weeks on pancreatitis concerns in patients taking diabetes drug Byetta, rose Thursday.

08/28/08 - 04:33 PM EDT

Politics Not Ruining Health Care Stocks

Kelli Hill, portfolio manager for the Old Mutual Large Cap Growth fund, explains why she's backing Varian Medical Systems and Johnson & Johnson.

08/28/08 - 04:19 PM EDT

Amylin Rising After Painful Beating

Shares were jumping more than 7% after being beaten down by concerns about diabetes drug Byetta.

08/28/08 - 10:19 AM EDT

Byetta Talk Leads Amylin to Fall Further

The stocks falls 25% Wednesday as Wall Street opines on recent cases of pancreatitis and deaths in patients taking the company's diabetes drug.

08/27/08 - 05:31 PM EDT

Health Winners & Losers: Cell Genesys

The stock takes a beating after company ends late-stage trial of GVAX.

08/27/08 - 04:55 PM EDT

Amedisys' CFO Carousel Misses the Mark

The company can't seem to keep a financial chief. Maybe the problem is higher up?

08/27/08 - 02:02 PM EDT